Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision
WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) — Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.”…
Pharmaceuticals, Biotechnology and Life Sciences
WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) — Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.”…
First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for…
Moderna reports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28), and expects 2025 revenue range of $1.5 to 2.5 billion andending cash balance of approximately $6 billion.
JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics…
MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical…
ZUG, Switzerland, Feb. 14, 2025 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a…
ZUG, Switzerland, Feb. 13, 2025 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a…
NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for…
BEDMINSTER, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (the “Company”) today announced that…
WARREN, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) — Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio (“Tevogen Bio…